Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.26 - $2.29
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$15.78M
Enterprise Value$3.34
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding44,338,573
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtHaving no reported debt materially reduces solvency and interest burden risk, preserving financial flexibility during a lengthy clinical development cycle. This durable balance-sheet strength makes it easier to prioritize R&D, negotiate partnerships, and access equity or non-dilutive financing on better terms over months.
Platform-focused Immuno-oncology PipelineA platform of engineered NK cell engagers (TriKE®/multi-specific constructs) provides structural upside: a modular modality can address multiple tumor antigens and indications, supporting pipeline breadth and repeatable product opportunities. If clinical proof emerges, platform scalability sustains longer-term growth potential.
Governance Change To Ease Shareholder ActionsLowering the quorum requirement is a durable governance adjustment that reduces the risk of repeated adjournments and speeds corporate decision-making, including financings or strategic transactions. This improves the company's ability to execute time-sensitive development or capital strategies over coming months.
Bears Say
Pre-revenue OperationsBeing pre-revenue is a structural constraint: with no product sales the company depends on external capital and clinical milestones to create value. Over a multi-month horizon, absence of revenue keeps profitability out of reach and heightens binary clinical and financing risks for long-term sustainability.
Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing cash consumption to fund R&D and trials. Without revenue, this persistent outflow creates runway pressure, increases likelihood of dilutive financings, and limits strategic optionality absent near-term financing or partnership funding.
Elevated Funding/continuity RiskVolatile shareholders' equity and prior negative book value reflect capital strain and intermittent recapitalizations. This structural funding uncertainty increases dilution risk and could constrain long-term R&D planning or partnership leverage until stable capital sources are secured.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $2.29 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $15.78M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on May 18, 2026. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.08.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 44,338,573 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went down -7.379%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
1.93%
Insiders
1.08% Mutual Funds
0.37% Other Institutional Investors
95.77% Public Companies and
Individual Investors